Ferrari G, King K, Rathbun K, Place C A, Packard M V, Bartlett J A, Bolognesi D P, Weinhold K J
Department of Surgery, Duke Centre for AIDS Research, Duke University Medical Centre, Durham, NC 27710-2996, USA.
Clin Exp Immunol. 1995 Aug;101(2):239-48. doi: 10.1111/j.1365-2249.1995.tb08345.x.
CD8+ cytotoxic T lymphocytes are an important component in the immunologic control of human viral diseases. IL-7, a stromal cell-derived cytokine, has been demonstrated to enhance both anti-tumour and anti-viral CTL as well as lymphokine-activated killer (LAK) activity. We studied the ability of IL-7 to support the activation and the growth of in vitro antigen-specific CTL precursors (CTLp) present in peripheral blood mononuclear cells (PBMC) from HIV-infected patients. Results from these studies demonstrate that inclusion of IL-7 in a vaccinia/HIV-1 vector-based stimulation strategy greatly augmented overall CTL reactivities, whereas addition of IL-7 to unstimulated cultures failed to induce any significant anti-viral cytolytic activity. In four of six patients, HIV-specific lytic activities were significantly higher in cultures stimulated with antigen plus IL-7 compared with in vitro stimulation (IVS) with antigen alone. Cytotoxic activity was principally mediated by CD8+ effector cells, and CD3+/CD8+ cell expansion was increased by 2.7-fold in the presence of IL-7. In PBMC from seronegative donors, IL-7 enhanced anti-vaccinia CTL activities with less effect on cell proliferation. Furthermore, anti-gag CTL frequencies determined by limiting dilution analysis were increased by 2- and 10-fold in two asymptomatic patients following IVS plus IL-7 compared with antigen stimulation alone. Cytofluorimetric analysis revealed that IL-7 preferentially expanded CD8 memory cells (CD45RO+) and CD8+ lymphocytes expressing activation molecules. IL-7 was also able to support the growth of CD4+ lymphocytes, while having no effect on natural killer (NK)/K lymphocytes. Taken together, these data suggest that IL-7 acts cooperatively with the antigen supporting in vitro maturation of CTLp into functional cytotoxic effectors. Thus IL-7 may be an important biologic entity to consider as part of future immune-based therapies in which ex vivo expansion of antigen-driven CTL is an important determinant.
CD8 + 细胞毒性T淋巴细胞是人体病毒性疾病免疫控制的重要组成部分。白细胞介素-7(IL-7)是一种由基质细胞产生的细胞因子,已被证明可增强抗肿瘤和抗病毒细胞毒性T淋巴细胞(CTL)以及淋巴因子激活的杀伤细胞(LAK)活性。我们研究了IL-7支持来自HIV感染患者外周血单核细胞(PBMC)中体外抗原特异性CTL前体(CTLp)激活和生长的能力。这些研究结果表明,在基于痘苗病毒/HIV-1载体的刺激策略中加入IL-7可大大增强总体CTL反应性,而在未刺激的培养物中添加IL-7未能诱导任何显著的抗病毒细胞溶解活性。在6例患者中的4例中,与单独用抗原进行体外刺激(IVS)相比,用抗原加IL-7刺激的培养物中HIV特异性溶解活性显著更高。细胞毒性活性主要由CD8 + 效应细胞介导,在存在IL-7的情况下,CD3 + /CD8 + 细胞扩增增加了2.7倍。在血清阴性供体的PBMC中,IL-7增强了抗痘苗CTL活性,对细胞增殖的影响较小。此外,通过有限稀释分析确定的抗gag CTL频率在两名无症状患者中,与单独抗原刺激相比,IVS加IL-7后增加了2倍和10倍。细胞荧光分析显示,IL-7优先扩增CD8记忆细胞(CD45RO +)和表达激活分子的CD8 +淋巴细胞。IL-7还能够支持CD4 +淋巴细胞的生长,而对自然杀伤(NK)/K淋巴细胞没有影响。综上所述,这些数据表明IL-7与抗原协同作用,支持CTLp体外成熟为功能性细胞毒性效应器。因此,IL-7可能是未来基于免疫的治疗中需要考虑的重要生物实体,其中体外扩增抗原驱动的CTL是一个重要决定因素。